1. Inicio
  2. Publicaciones
  3. Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in HLA-matched and haploidentical donor transplants for patients with Hodgkin lymphoma: a comparative study of the LWP EBMT.: GVHD prophylaxis for patients with Hodgkin lymphoma.

Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in HLA-matched and haploidentical donor transplants for patients with Hodgkin lymphoma: a comparative study of the LWP EBMT.: GVHD prophylaxis for patients with Hodgkin lymphoma.

Fecha de publicación: Fecha Ahead of Print:

Autores de IDIVAL

Autores ajenos al IDIVAL

  • Montoro J
  • Boumendil A
  • Finel H
  • Bramanti S
  • Castagna L
  • Blaise D
  • Dominietto A
  • Kulagin A
  • Yakoub-Agha I
  • Tbakhi A
  • Solano C
  • Giebel S
  • Gulbas Z
  • López Corral L
  • Pérez-Simón JA
  • Díez Martín JL
  • Farina L
  • Koc Y
  • Socié G
  • Arat M
  • Jurado M
  • Labussière-Wallet H
  • Villalba M
  • Ciceri F
  • Martinez C
  • Nagler A
  • Sureda A
  • Glass B

Unidades

Abstract

BACKGROUND: Post-transplant cyclophosphamide (PTCy) has emerged as a promising approach for preventing graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, there is a lack of studies examining the impact of this GVHD prophylaxis when different donor types are used in patients with Hodgkin lymphoma (HL). OBJECTIVE: To compare the outcomes of patients with HL undergoing HSCT from both HLA-matched donors, which include matched sibling donors (MSD) and matched unrelated donors (MUD), and haploidentical donors, using PTCy as GVHD prophylaxis approach in all cohorts. STUDY DESIGN: We retrospectively compared transplant outcomes of allo-HSCT from 166 HLA-matched donors (96 siblings and 70 unrelated) and 694 haploidentical donors using PTCy-based GVHD prophylaxis in patients with HL registered in the EBMT database from 2010 to 2020. RESULTS: Haploidentical transplantation showed significantly lower platelet engraftment (86% vs 94%, p<0.001) and higher rates of grades II-IV acute GVHD (24% vs 34%, p=0.01) compared to HLA-matched transplantation. The 2-year cumulative incidence of non-relapse mortality (NRM) was significantly lower in the HLA-matched cohort compared to haploidentical cohort (10% vs 18%, p=0.02), resulting in a higher overall survival (OS) rate (82% vs 70%, p=0.002). There were no significant differences observed in terms of relapse, progression-free survival, or GVHD-free relapse-free survival between the groups. In multivariable analysis, haploidentical transplantation was associated with an increased risk of grades II-IV acute GVHD, NRM, and worse OS compared to HLA-matched transplantation. CONCLUSIONS: Our findings suggest that, in the context of PTCy-based GVHD prophylaxis, transplantation from HLA-matched donors appears to be a more favorable option compared to haploidentical transplantation.

Copyright © 2023. Published by Elsevier Inc.

Datos de la publicación

ISSN/ISSNe:
2666-6375, 2666-6367

Transplantation And Cellular Therapy  ELSEVIER SCIENCE INC

Tipo:
Article
Páginas:
-
PubMed:
38043802

Citas Recibidas en Web of Science: 8

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Hodgkin lymphoma; Post-transplant cyclophosphamide; allogeneic hematopoietic stem cell transplantation; graft-versus-host disease

Compartir